A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002332
- Lead Sponsor
- Immunobiology Research Institute
- Brief Summary
To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
- Detailed Description
Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Dr Jeffrey Galpin
🇺🇸Tarzana, California, United States
Dr Marcus Conant
🇺🇸San Francisco, California, United States
Novum Inc
🇺🇸Pittsburgh, Pennsylvania, United States